Pharmac is reconsidering whether or not it will continue to fund the RSV drug Palivizumab.

It planned to stop funding, but it's now rethinking that after new information.

Auckland University Associate Professor Jane Alsweiler says the drug is highly effective at keeping babies out of hospital.

Pharmac Chief Medical Officer David Hughes says the past source of funding has dried up.

"Additional Covid-19 pandemic funding from the Government- that funding has ended. And that means Palivizumab needs to be considered through Pharmac's usual process."

LISTEN ABOVE